TSOI Subsidiary, SandBox Dental Labs, files 510(k) with FDA

Company Seeks Market Clearance for Oral Appliance To Treat Moderate Obstructive Sleep Apnea

Read More

TSOI Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

TSOI files Patent on Methods of Re-Activating Dormant Memory Cells with Anticancer Activity

Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI Announces Exclusive Patent License Agreement with Subsidiary Emvolio, Inc.

Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

TSOI files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI Announces Exclusive Patent License Agreement to innaMune with its Subsidiary Emvolio, Inc.

Company Developing Proprietary Products that Help Immune System Fight Cancer

Read More

TSOI files Patent on Blood Derived Innate Immune System Stimulator

Company Resurrecting “Transfer Factor” Immunotherapeutic for Treatment of Cancer

Read More

TSOI Announces Exclusive Patent License Agreement with its Subsidiary Emvolio, Inc.

Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

TSOI files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants

Company Developing Proprietary Nutraceutical Products that Help Modulate Immune System

Read More

TSOI Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc.

Emvolio is developing products that can be used together to attack cancer at different levels,
as well as be used alone or in combination with existing therapies

Read More

SandBox Dental Labs, Inc. – is a majority owned subsidiary of TSI consisting of a dental laboratory to manufacture and fill prescriptions from dentists who will use our proprietary Sleep Appliance to treat their patients with mild to moderate obstructive sleep apnea.

Emvolio, Inc. – is a majority owned subsidiary of TSI where the intellectual property surrounding immune-oncology is housed.  The Company is developing products that can be used together to attack cancer at different levels, as well as to be used alone or in combination with existing therapies.

OmniBiome, Inc. – is a majority owned subsidiary of TSI where the intellectual property surrounding probiotics is housed. Current programs focus on the use of probiotics to prevent pre-term labor and on using probiotics to reverse periodontal disease.

Nutraceutical Division – TSI has been producing very high quality nutraceuticals. Its flagship product, Projuvenol®, is a Patented (No. 9,682,047) proprietary mixture containing pterostilbene – one of the most potent antioxidants known.